Why are data-driven benchmarks important in healthcare?

Data-driven benchmarks provide crucial insights into the efficiency and effectiveness of healthcare processes. They enable organizations to identify areas for improvement, enhance performance, and ensure compliance with industry standards.

How can healthcare organizations improve their promotional review processes?

Organizations can improve their promotional review processes by employing data-driven benchmarks and metrics. This approach helps identify inefficiencies, streamline operations, and support strategic decision-making.

What role does performance measurement play in medical product commercialization?

Performance measurement is vital in ensuring that medical products are commercialized effectively. By tracking key performance indicators, organizations can optimize their marketing strategies, manage resources better, and achieve regulatory compliance efficiently.

‹ Back to Industries Healthcare

Unlock Hidden Potential in Healthcare: Data-Driven Benchmarks Reveal Efficiency Gains in Reviews

Annalise Ludtke from Vodori discusses the importance of data-driven benchmarks in healthcare promotional review processes. The conversation features insights from Scott Rovegno, exploring strategies for improving efficiency and effectiveness in medical product commercialization. The session emphasizes using performance measurement to enhance healthcare operations.

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Promoted content from Vodori on MarketScale.

By Annalise Ludtke · March 5, 2024, 3:49 PM UTCAnnalise LudtkeHealthcare industryHealthcare StrategyPromotional Review Process

Unlock Hidden Potential in Healthcare: Data-Driven Benchmarks Reveal Efficiency Gains in Reviews

Key takeaways

Promotional review processes benefit significantly from data-driven benchmarks.

Improving operational efficiency in healthcare requires continuous performance measurement.

Strategic insights facilitate the advancement of healthcare product commercialization.

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

In an era where the healthcare industry is increasingly data-driven, understanding the nuances of promotional review processes becomes crucial for innovation and efficiency. The Benchmarks Symposium hosted by Vodori provides a deep dive into the state of promotional review benchmarks in 2023.

This episode led by Annalise Ludtke, the Senior Manager of Marketing and Communications at Vodori, features a conversation with Scott Revegno, Co-founder and CEO of Vodori. They explore the importance of data and benchmarks in the promotional review process, discussing strategies for continuous improvement and operational efficiency. Through their dialogue, they underscore the critical role of measuring performance to effectively manage and enhance medical product commercialization.

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featured See how it works15 minutes, straight to a calendar.

About the author

Annalise Ludtke

Your experts, this publication

MarketScale turns your clinicians, service-line leaders, and field engineers into coverage like this.

Book a demo Start free

MarketScale platform

Want to launch your own Healthcare podcast or show?

MarketScale gives Healthcare B2B marketing teams a full content studio: record, produce, and distribute your own channel. No agency, no crew, no guessing.

See how it works →

B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Keep exploring

Executive Thought Leadership
Put clinical leaders on the record.
State of GEO & AI Visibility
How B2B brands get cited by AI search.

healthcare Events

Healthcare Design Expo & Conference 2026

Oct 17, 2026 · New Orleans, LA

HLTH 2026

Nov 15, 2026 · Las Vegas, NV

See all healthcare events ›

Become a Healthcare Voice

Share your Healthcare expertise with B2B marketing teams across MarketScale’s 1,250+ brand network.

Apply to participate

B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Explore your AI visibility →Book a demo

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

Start free →Book a demo

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people

One professional video edit a month for qualifying companies

Media requests to your crowd, remote recording, AI writing tools

$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended AstraZeneca and Daiichi Sankyo’s Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly is investing $6.5 billion in a Houston manufacturing facility set to open around 2030, primarily to scale production of Foundayo, its oral GLP-1 treatment. The project signals a broader shift in U.S. pharmaceutical manufacturing reshoring and underscores the supply chain challenge of forecasting demand and building capacity years in advance for breakthrough therapeutics.

01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
02GLP-1 demand forecasting remains highly uncertain: Lilly's CEO noted that one-third of new GLP-1 pill patients are now choosing Foundayo, illustrating fast-moving market share shifts that complicate production planning years in advance
03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

Waiting for perfectly clean data is stalling healthcare AI, not protecting it

Healthcare organizations often delay AI initiatives waiting for perfectly clean data, but this assumption no longer holds: reliable subsets and synthetic data allow projects to start now while data work continues in parallel. Success requires starting with business outcomes rather than technology capabilities, and embedding governance in product strategy before implementation, not after.

01Waiting for 100% clean data is effectively a decision never to start; hospital AI projects can begin on reliable data subsets while quality work continues in parallel.
02Frame AI decisions around business outcomes (revenue growth, cost reduction, competitive advantage, new products, or ecosystem influence) rather than asking what AI can do.
03Governance should be part of product strategy before design or purchase, especially as agentic AI takes actions—such as handling many revenue-cycle denials—while routing the rest to humans.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

About the Experts

Annalise Ludtke

Senior Manager of Marketing and Communications at Vodori

Annalise Ludtke is responsible for shaping marketing and communications strategies at Vodori. Her work focuses on enhancing the efficiency of promotional review processes in the healthcare sector. She plays a key role in leveraging data-driven insights to drive operational improvements.

LinkedIn Company

Scott Rovegno

Co-founder and CEO

Vodori

For Healthcare teams

See how Healthcare teams use MarketScale →

Executive Thought Leadership

Explore Channels

Industry news, analysis, and expert perspectives

Professional AV›Engineering & Construction›Education Technology›Healthcare›Energy›Software & Technology›Retail›Business Services›Industrial IoT›Sports & Entertainment›Transportation›Sciences›Building Management›Food & Beverage›Architecture & Design›Hospitality›Marketing Tech›

Keep exploring

More from Healthcare

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512